Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 0.84 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ADH1B | P00325 | 1/20 | 0.55 |
| ▸ | ADH1C | P00326 | 1/20 | 0.55 |
| ▸ | ADH1A | P07327 | 1/20 | 0.55 |
| ▸ | ADH4 | P08319 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonanal SCHEMBL1697203 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL371426 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL154928 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Undecanal SCHEMBL1871746 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL3118926 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Decanal SCHEMBL10857921 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL371480 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL1696133 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Tetradecanal SCHEMBL10857929 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL15136035 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. DELAWARE | 2008-02-21 | — | — | US | claimed |
| WO-2007117581-A2 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070116757-A1 | Methylene Blue Derivatives | COLLEGIUM PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007056439-A1 | SALTS OF METHYLENE BLUE AND ITS DERIVATIVES | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-4591884-A1 | LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, AND RELATED USE AND MEDICAMENT COMPRISING SAME | Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd. (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-3403840-B1 | PRETREATMENT SOLUTION, INK SET AND METHOD FOR PRODUCING PRINTED MATTER | TOYO INK SC HOLDINGS CO LTD (JP) | 2023-04-12 | — | — | EP | disclosed |
| US-11613665-B2 | Water-based ink for inkjet and method for producing printed matter | TOYO INK SC HOLDINGS CO., LTD. (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20230089244-A1 | AQUEOUS INKJET INK AND PRINTED ITEM | TOYO INK SC HOLDING CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3647380-B1 | WATER-BASED INKJET INK AND PRODUCTION METHOD FOR PRINTED MATTER | TOYO INK SC HOLDINGS CO LTD (JP) | 2023-01-25 | — | — | EP | disclosed |
| EP-4116382-A1 | WATER-BASED INK-JET INK AND PRINTED MATTER | Toyo Ink SC Holdings Co., Ltd. (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-3517584-B1 | PRETREATMENT SOLUTION, INK SET AND METHOD FOR PRODUCING PRINTED MATTER | TOYO INK SC HOLDINGS CO LTD (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220195223-A1 | AQUEOUS INKJET INK, AQUEOUS INKJET INK SET, AQUEOUS INKJET INK PRINTED MATTER PRODUCTION METHOD, AND PRINTED MATTER | TOYO INK SC HOLDINGS CO., LTD (JP) | 2022-06-23 | — | — | US | disclosed |
| EP-2985323-A1 | AQUEOUS INK FOR INKJET USE, AND PRINTING METHOD | Toyo Ink SC Holdings Co., Ltd. (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-20100028469-A1 | Extracts of Cranberry and Methods of Using Thereof | HERBALSCIENCE GROUP, LLC (US) | 2010-02-04 | — | — | US | disclosed |
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. DELAWARE | 2008-02-21 | — | — | US | disclosed |
| WO-2007117581-A2 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007056439-A1 | SALTS OF METHYLENE BLUE AND ITS DERIVATIVES | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-6060644-A | BIOSYNTHESIS OF PLANT LIPIDS, AND SPECIFICALLY RELATES TO THE ISOLATION AND USE OF CLONED CUTICULAR LIPID GENES. | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0638588-A1 | Derivatives of 6,7-Dihydroxy-4-thiaheptonic acid and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0503508-A1 | Vesicles and polymeric vesicles | Kao Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070116757-A1 | Methylene Blue Derivatives | ACMSD, SI, HTR2B | TSHR 4306/4885FAAH 412/4885TRPV1 300/4885 |
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | BDNF, FFAR4, FFAR2 | TSHR 1885/4885FAAH 126/4885TRPV1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.